Yifan Pharmaceutical’s F-627 Receives NMPA Approval for Neutropenia Treatment in Cancer Patients
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a China-based pharmaceutical company, has announced receiving market approval...
Jiangsu Nhwa Pharmaceutical Receives NMPA Approval for Olinvyk (Oliceridine) Injection
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), a China-based pharmaceutical company, has announced that it...
Innovent Biologics’ Tyvyt Secures NMPA Approval for EGFR-Mutated NSCLC Treatment
China-based Innovent Biologics Inc., (HKG: 1801) has announced that the National Medical Products Administration (NMPA)...
China’s NHC Releases Draft Guidelines for Somatic Cell Clinical Research, Seeks Public Input
The National Health Commission (NHC) has released the “Somatic Cell Clinical Research Guidelines (draft proposal)”...
Zion Pharma’s ZN-A-1041 Acquired by Roche for Global Development and Commercialization
China-based Zion Pharma Ltd, a biotechnology company specializing in the development of brain-penetrable compounds, has...
Grand Pharmaceutical Group Files NDA for Ophthalmic Analgesic APP13007 with US FDA
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the filing of a New Drug...
Neuro3 Therapeutics Secures Exclusive License Deal with Lundbeck for KCNQ2 Activator Programs
Neuro3 Therapeutics (Neuro3), a biotechnology company specializing in central nervous system (CNS) diseases with operations...
Organon Reports Q1 2023 Revenue Growth, Highlights Women’s Health and Biosimilars Progress
Organon (NYSE: OGN) has released its financial report for the first quarter of 2023, announcing...
US FDA Nears Regulatory Decision on Junshi Biosciences’ PD-1 Inhibitor Tuoyi
China-based Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is approaching a significant regulatory milestone...
Acorda Therapeutics Strikes Deal with Hangzhou Chance for Inbrija Distribution in China
US-based Acorda Therapeutics Inc., (Nasdaq: ACOR) has announced a distribution and supply agreement with Hangzhou...
RemeGen Ltd Receives Approval for Phase I Clinical Study of RC198 in Solid Tumors
RemeGen Ltd (HKG: 9995) has announced that it has received approval from the Human Research...
Grand Pharmaceutical Group Completes Enrollment in Phase III Study for Ryaltris Nasal Spray
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the completion of all subject enrollment...
Alphamab Oncology and CSPC Pharma Get Green Light for KN026 Phase III Study in Breast Cancer
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced receiving...
Eyenovia, Inc. Receives FDA Approval for Mydcombi, a First-of-Its-Kind Ophthalmic Spray
US-based Eyenovia, Inc. (NASDAQ: EYEN) has announced obtaining market approval from the US Food and...
NMPA Releases 67th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 67th batch of reference drugs for...
Jiangsu Hengrui Pharmaceuticals Advances SHR-1819, SHR-2002, and Adebrelimab into New Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals for its...
Ascletis Pharma Receives Approval for Phase IIa Study of ASC10 for RSV Infection
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the green light to conduct a...
EQRx Inc. Abandons Plans for Low-Cost Drugs, Terminates Development of Three China-Sourced Products
US-based biotech EQRx Inc., (Nasdaq: EQRX) has disclosed in its Q4 2022 financial report a...
Shunxi Holding Group Secures Licensing Deal for Cartherics’ CTH-004 in Greater China
China-based Shunxi Holding Group Co. Ltd has entered into a licensing deal with Australia-based firm...
AstraZeneca’s MEK Inhibitor Koselugo Approved in China for Pediatric NF1-Related PN
UK major AstraZeneca (AZ, NASDAQ: AZN) has announced that its mitogen-activated protein kinase (MEK) inhibitor,...